Epigenomic insights and computational advances in hematologic malignancies

Area of Science:

• Hematology
• Oncology
• Genetics
• Epigenetics

Background:

• Hematologic malignancies (HMs) are diverse cancers of blood, bone marrow, and lymphatics.
• Myeloid malignancies present complex genetic and epigenetic challenges in diagnosis and therapy.
• Understanding these landscapes is crucial for improving patient outcomes.

Purpose of the Study:

• To review the classification, prevalence, and incidence of myeloid malignancies.
• To analyze the interplay of genetic and epigenetic factors in disease progression and resistance.
• To highlight advancements in diagnostic and therapeutic strategies, emphasizing precision medicine.

Main Methods:

• Detailed examination of genetic alterations (translocations, mutations, CNVs) and epigenetic modifications (DNA methylation).
• Exploration of diagnostic modalities including nano-agents, optical imaging, flow cytometry, ctDNA, and mutation testing.
• Emphasis on machine learning for epigenetic data analysis and computational advancements for data integration.

Main Results:

• DNA methylation episignatures are key for sensitive and specific diagnostic/prognostic assays in clinical practice.
• Integration of genomic and epigenomic profiling accelerates biomarker discovery and clinical translation.
• AI and comprehensive genomic datasets provide actionable insights for myeloid malignancy management.

Conclusions:

• Precision medicine and epigenomic research are transforming myeloid malignancy diagnosis and treatment.
• Advancements in computational biology and AI are crucial for optimizing patient management.
• Translational potential of these innovations offers tangible benefits for patient care and outcomes.